candesartan has been researched along with Idiopathic Parkinson Disease in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulisevsky, J | 1 |
| Martínez-Horta, S | 1 |
| Campolongo, A | 1 |
| Pascual-Sedano, B | 1 |
| Marín-Lahoz, J | 1 |
| Bejr-Kasem, H | 1 |
| Labandeira-Garcia, JL | 4 |
| Lanciego, JL | 2 |
| Puig-Davi, A | 1 |
| Horta-Barba, A | 1 |
| Pagonabarraga, J | 1 |
| Rodríguez-Antigüedad, J | 1 |
| Muñoz, A | 1 |
| Garrido-Gil, P | 1 |
| Dominguez-Meijide, A | 1 |
| Rodriguez-Perez, AI | 2 |
| Valenzuela, R | 2 |
| Villar-Cheda, B | 2 |
| Guerra, MJ | 2 |
1 trial available for candesartan and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease.
Topics: Benzimidazoles; Cognition Disorders; Cognitive Dysfunction; Humans; Neuropsychological Tests; Parkin | 2023 |
3 other studies available for candesartan and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimida | 2014 |
Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Cell Death; Dopamine; Estradiol; Estrog | 2010 |
Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Co | 2012 |